PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients

Thymic epithelial tumors are rare neoplastic proliferations of thymic epithelial cells. The aggressiveness of these malignancies increases as higher is the histologic subtype, being thymic carcinoma the most aggressive subtype, with a greater tendency to metastatic spread. In metastatic setting, the...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2022-05, Vol.23 (3), p.e243-e246
Main Authors: Remon, Jordi, Girard, Nicolas, Novello, Silvia, de Castro, Javier, Bigay-Game, Laurence, Bernabé, Reyes, Greillier, Laurent, Mosquera, Joaquin, Cousin, Sophie, Juan, Oscar, Sampayo, Miguel, Besse, Benjamin
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Human health and pathology
Humans
Immunology
Immunotherapy
Lenvatinib
Life Sciences
Lung Neoplasms - drug therapy
Pembrolizumab
Phenylurea Compounds
Pulmonology and respiratory tract
Quinolines
Second-line
Thymic epithelial tumors
Thymoma - pathology
Thymus Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thymic epithelial tumors are rare neoplastic proliferations of thymic epithelial cells. The aggressiveness of these malignancies increases as higher is the histologic subtype, being thymic carcinoma the most aggressive subtype, with a greater tendency to metastatic spread. In metastatic setting, there is no standard treatment after progression on platinum-based chemotherapy. In this scenario, monotherapy treatment either with lenvatinib, a multi-tyrosine kinase inhibitor with antiangiogenic properties, or pembrolizumab, an immune-checkpoint inhibitor, has reported clinical activity. Potential combination of both agents may have synergistic activity as reported in other cancer types. PECATI trial is a single-arm, investigator-initiated phase II study aiming to assess the activity and safety of the combination of lenvatinib and pembrolizumab in 43 patients with advanced B3-thymoma or thymic carcinoma who progressed on or after at least one previous line of platinum-based chemotherapy. The primary endpoint of the trial is 5-month progression-free survival rate and the secondary endpoints include overall response rate, duration of response, and overall survival.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2021.07.008